Cereno Scientific participates at the upcoming medical conference ACC.24 to further build presence in the Cardiology community
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for common and rare cardiovascular disease, today announced presence at ACC’s 73rd Annual Scientific Session & Expo (ACC.24) organized by the American College of Cardiology. The event is held between April 6–8, 2024 in Atlanta, Georgia, USA.“Participating at leading cardiology congresses, such as ACC.24, is an important aspect of our strategy to continue to raise awareness about our portfolio of innovative drug candidates, learn about the most recent advances and expand our network among